Drugs / PED-HZ/su
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04006808 | Oct 2019 → May 2026 overdue | herpes zoster | GlaxoSmithKline | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PED-HZ/su | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04006808 ↗ |
| Known as | GSK143713A | “A Reactogenicity, Safety and Immunogenicity Study of GSK's Paediatric Herpes Zoster Subunit Candidate Vaccine (PED-HZ/su) GSK143713A in Immunocompromised Paediatric Renal...” NCT04006808 ↗ |
| Modality | Vaccine | “GSK's candidate vaccine- PED-HZ/su.” NCT04006808 ↗ |
| Route | Intramuscular | “is administered intramuscularly in the deltoid of the non-dominant arm” NCT04006808 ↗ |